NASDAQ: NVAXNovavax Inc Stock Ownership - Who owns Novavax?
Insider buying vs selling
Have Novavax Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| John C. Jacobs | President and CEO | 2026-01-23 | 39,132 | $9.17 | $358.84kSell |
| Mark J. Casey | EVP Chief Legal Officer | 2025-12-11 | 12,713 | $6.69 | $85.05kSell |
| Ruxandra Draghiaakli | Section 16 | 2025-11-11 | 6,048 | $7.40 | $44.76kSell |
| James Patrick Kelly | EVP CFO and Treasurer | 2025-03-07 | 5,904 | $8.34 | $49.24kSell |
| John Trizzino | President and COO | 2025-03-07 | 13,954 | $8.34 | $116.38kSell |
| John Trizzino | President and COO | 2025-03-01 | 23,185 | $8.33 | $193.13kSell |
| James Patrick Kelly | EVP CFO and Treasurer | 2025-03-01 | 28,337 | $8.33 | $236.05kSell |
| John C. Jacobs | President and CEO | 2025-03-01 | 38,451 | $8.33 | $320.30kSell |
| Mark J. Casey | EVP Chief Legal Officer | 2025-03-01 | 1,214 | $8.33 | $10.11kSell |
| Elaine Ohara | EVP Chief Strategy Officer | 2025-03-01 | 5,375 | $8.33 | $44.77kSell |
NVAX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when NVAX insiders and whales buy or sell their stock.
NVAX Shareholders
What type of owners hold Novavax Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Vanguard Group Inc | 9.35% | 15,194,563 | $127.18M | Institution |
| Blackrock Inc | 7.86% | 12,773,053 | $106.91M | Institution |
| Shah Capital Management | 7.27% | 11,811,780 | $98.86M | Institution |
| Cadila Pharmaceuticals Ltd | 5.85% | 9,500,000 | $79.52M | Insider |
| State Street Corp | 4.43% | 7,196,719 | $60.24M | Institution |
| Sanofi | 4.23% | 6,880,481 | $57.59M | Institution |
| James B. 1. Tananbaum | 3.86% | 6,268,455 | $52.47M | Insider |
| D E Shaw Co Inc | 2.63% | 4,274,079 | $35.77M | Institution |
| Sj Strategic Investments LLC | 2.46% | 4,001,500 | $33.49M | Insider |
| Coatue Management LLC | 2.36% | 3,836,986 | $32.12M | Institution |
NVAX vs Biotech Stocks
Novavax Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.